Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer; HER2-positive; Metastatic
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Placebo|DRUG: Taxane|DRUG: Pertuzumab|DRUG: Trastuzumab
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo